Abstract
Multiple myeloma accounts for approximately 10% of hematologic malignancies, the frequency is constantly increasing due to aging of the general population.1,2 Recently, novel agents, such as thalidomide, bortezomib and lenalidomide have shown significant activity in multiple myeloma. Combinations of these agents with steroids, alkylating agents or anthracyclines have significantly improved response rate and progression- free survival (PFS). In elderly patients, older than 65 years, oral melphalan and prednisone (MP) has been combined with thalidomide or bortezomib significantly improving response rate and PFS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.